Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Radiotherapy for laryngeal cancers
Abstract
We present the update of the recommendations of the French society of oncological radiotherapy on radiotherapy of laryngeal cancers. Intensity modulated radiotherapy is the standard of care radiotherapy for the management of laryngeal cancers. Early stage T1 or T2 tumours can be treated either by radiotherapy or conservative surgery. For tumours requiring total laryngectomy (T2 or T3), an organ preservation strategy by either induction chemotherapy followed by radiotherapy or chemoradiotherapy with cisplatin is recommended. For T4 tumours, a total laryngectomy followed by radiotherapy is recommended when feasible. Dose regimens for definitive and postoperative radiotherapy are detailed in this article, as well as the selection and delineation of tumour and lymph node target volumes.
Source and rights
Published by Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2022. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Published
- 2022
- Applies to
- 🇪🇺 Europe
- Scope
- Regional
- Journal
- Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
- PubMed











